RTP Mobile Logo
Year in Review: Proceedings from a Multitumor CME Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers
Released March 2017

Proceedings from a daylong symposium featuring key clinical presentations and papers in lung cancer, gastrointestinal cancers, melanoma, genitourinary cancers, multiple myeloma, breast cancer and Hodgkin and non-Hodgkin lymphoma. Including perspectives from Drs Kenneth C Anderson, Tanios Bekaii-Saab, Ian W Flinn, William J Gradishar, Melissa Johnson, Jason J Luke, Loretta J Nastoupil, Robert Z Orlowski, Geoffrey R Oxnard, Philip A Philip, Elizabeth R Plimack, David I Quinn, Naiyer Rizvi, George W Sledge Jr, Jeffrey Weber and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across lung cancer, gastrointestinal cancers, melanoma, genitourinary cancers, multiple myeloma, breast cancer and Hodgkin and non-Hodgkin lymphoma to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity enables the participant to earn up to 7 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YiRMultitumor16/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kenneth C Anderson, MD
    Kraft Family Professor of Medicine
    Harvard Medical School
    Director, Jerome Lipper Multiple Myeloma Center
    Director, LeBow Institute for Myeloma Therapeutics
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.

    Tanios Bekaii-Saab, MD
    Co-Leader
    GI Cancer Program
    Mayo Clinic Cancer Center
    Senior Associate Consultant
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Consulting Agreements: Bayer HealthCare Pharmaceu­ticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Merck, Taiho Oncology Inc; Data and Safety Monitoring Board: Exelixis Inc, Silagen.

    Ian W Flinn, MD, PhD
    Director of Blood Cancer Research
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Contracted Research: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Takeda Oncology.

    William J Gradishar, MD
    Betsy Bramsen Professor of Breast Oncology
    Professor of Medicine
    Director, Maggie Daley Center for Women’s Cancer Care
    Robert H Lurie Comprehensive Cancer Center
    Northwestern University
    Feinberg School of Medicine
    Chicago, Illinois

    No relevant conflicts of interest to disclose.

    Melissa Johnson, MD
    Associate Director
    Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: Astellas Pharma Global Development Inc, Otsuka Pharmaceutical Co Ltd.

    Jason J Luke, MD
    Assistant Professor of Medicine
    University of Chicago
    Chicago, Illinois

    Consulting Agreements: Amgen Inc, Array BioPharma Inc; Contracted Research: AbbVie Inc, BBI Therapeutics, Bristol-Myers Squibb Company, Celldex Therapeutics, Corvus Pharmaceuticals, Delcath Systems Inc, EMD Serono Inc, Five Prime Therapeutics Inc, Genentech BioOncology, Incyte Corporation, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company.

    Loretta J Nastoupil, MD
    Assistant Professor
    Department of Lymphoma/Myeloma
    Division of Cancer Medicine
    Director, Lymphoma Outcomes Database
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Gilead Sciences Inc, Janssen Biotech Inc, TG Therapeutics Inc; Consulting Agreement: Gilead Sciences Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, TG Therapeutics Inc.

    Robert Z Orlowski, MD, PhD
    Director, Myeloma Section
    Florence Maude Thomas Cancer Research Professor
    Departments of Lymphoma/Myeloma and Experimental Therapeutics
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.

    Geoffrey R Oxnard, MD
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: ARIAD Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Inivata, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc.

    Philip A Philip, MD, PhD
    Professor of Oncology and Medicine
    Director of GI and Neuroendocrine Tumors
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committee: bioTheranostics Inc, Caris Life Sciences, Celgene Corporation, EMD Serono Inc, Halozyme Therapeutics, Lexicon Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc; Contracted Research: Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Taiho Oncology Inc, XBiotech; Speakers Bureau: Amgen Inc, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

    Elizabeth R Plimack, MD, MS
    Director, Genitourinary Clinical Research
    Associate Professor
    Department of Hematology/Oncology
    Fox Chase Cancer Center
    Temple Health
    Philadelphia, Pennsylvania

    Advisory Committee: Acceleron Pharma, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: Bristol-Myers Squibb Company, Lilly, Pfizer Inc; Contracted Research: Acceleron Pharma, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, GlaxoSmithKline, Lilly, Merck, Pfizer Inc.

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC/Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Exelixis Inc, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi.

    Naiyer Rizvi, MD
    Professor of Medicine
    Director of Thoracic Oncology and Phase I Immunotherapeutics
    Price Chair in Clinical Translational Research
    Columbia University Medical Center
    New York, New York

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Merck, Novartis Pharma­ceuticals Corporation, Roche Laboratories Inc; Ownership Interest: Gritstone Oncology.

    George W Sledge Jr, MD
    Professor of Medicine
    Chief, Division of Oncology
    Department of Medicine
    Stanford University School of Medicine
    Stanford, California

    Board of Directors: Syndax Pharmaceuticals Inc; Contracted Research: Lilly; Scientific Advisory Board: Nektar, Radius Health Inc, Symphogen A/S.

    Jeffrey Weber, MD, PhD
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    Professor of Medicine
    NYU Langone Medical Center
    New York, New York

    Advisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation; Stock Ownership: Altor Bioscience Corp, Celldex Therapeutics, CytomX Therapeutics; Scientific Advisory Board: Altor Bioscience Corp, Celldex Therapeutics, CytomX Therapeutics, Lion Biotechnologies.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Therapeutics, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, bioTheranostics Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Janssen Biotech Inc, Lilly, Medivation Inc, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Sanofi, Seattle Genetics, Taiho Oncology Inc and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2017
    Expiration date: March 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Topics:

Introduction: Dr Love

Lung Cancer

  • Chemotherapeutic and Immunotherapeutic Approaches to Wild-Type NSCLC, SCLC and Mesothelioma: Dr Rizvi
  • Management of Patients with EGFR, ALK or ROS1 Alterations: Dr Oxnard
  • Targeted Therapies for Uncommon Mutations in NSCLC; Novel Agents for SCLC: Dr Johnson

Breast Cancer

  • Novel Chemotherapy Options, Immunotherapy and Treatment Strategies for HER2-Positive and Triple-Negative Breast Cancer: Dr Sledge
  • Genomic Assays and Novel Treatment Strategies for ER-Positive Breast Cancer: Dr Gradishar

Melanoma

  • Talimogene Laherparepvec, Single-Agent Checkpoint Inhibitor Data and Immune-Related Response Criteria in Melanoma: Dr Luke
  • Combination Checkpoint Inhibitor Regimens; Treatment of BRAF V600- or NRAS-Mutant Melanoma: Dr Weber

Genitourinary Cancers

  • Endocrine and Bone-Targeted Therapy for Prostate Cancer: Dr Quinn
  • Novel Approaches to the Management of Renal Cell and Urothelial Bladder Cancer: Dr Plimack

Hodgkin and Non-Hodgkin Lymphomas

  • Chronic Lymphocytic Leukemia: Dr Williams
  • Follicular, Diffuse Large B-Cell and Mantle Cell Lymphomas; Dr Flinn
  • Hodgkin and T-Cell Lymphomas: Dr Nastoupil

Multiple Myeloma

  • Management of Newly Diagnosed Myeloma and Smoldering Myeloma: Dr Orlowski
  • Management of Relapsed Myeloma and Incorporation of Novel Agents: Ixazomib, Daratumumab, Elotuzumab and Checkpoint Inhibitors: Dr Anderson

Colorectal, Gastric and Pancreatic Cancer

  • Emerging Data on the Treatment of Metastatic Colorectal and Gastric Cancers: Dr Philip
  • Emerging Treatment Options for Noncolorectal GI Cancers: Dr Bekaii-Saab